CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

November 16, 2026 · Phase 3 readout

OTSKF Phase 3 readout: a positive outcome, +5.9%

On November 16, 2026, Delamanid (DLM) — OTSUKA (Tuberculosis, MDR) reached its Phase 3 readout. The result was a positive outcome, and the stock moved +5.9% in the window around the event.

The move

$73.15
1d before
$77.50
Event day
$77.50
1d after
$77.50
5d after

Our prediction vs. the result

CatalystAlert called this one neutral (+0.6% expected); the stock actually moved +5.9%. Model confidence at the time: 49%.

See the full scored track record

Pre-catalyst setup

+0.0%
30-day run-up
0%
30-day volatility